James Rowe is a distinguished British neurologist and neuroscientist who has made significant contributions to the understanding of neurodegenerative diseases, particularly frontotemporal dementia (FTD) and related disorders affecting movement and cognition. Based at Cambridge University, Rowe holds a professorial position in Clinical Neurology and serves as a leading researcher within the neurodegenerative disease community. His work bridges clinical neurology with advanced neuroimaging and molecular research, establishing him as a key figure in contemporary neurodegeneration research.
Function/Biology
In his clinical and research roles, Rowe specializes in the diagnosis and investigation of complex neurodegenerative conditions that present with overlapping motor and cognitive symptoms. His expertise encompasses the full spectrum of frontotemporal lobar degeneration (FTLD) disorders, including behavioral variant frontotemporal dementia (bvFTD), primary progressive aphasia (PPA), and disorders with prominent motor features such as progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). Rowe utilizes advanced neuroimaging techniques, including structural and functional magnetic resonance imaging (MRI), positron emission tomography (PET), and diffusion tensor imaging (DTI), to characterize the pathological changes occurring in these conditions.
Role in Neurodegeneration
...
James Rowe
Overview
James Rowe is a distinguished British neurologist and neuroscientist who has made significant contributions to the understanding of neurodegenerative diseases, particularly frontotemporal dementia (FTD) and related disorders affecting movement and cognition. Based at Cambridge University, Rowe holds a professorial position in Clinical Neurology and serves as a leading researcher within the neurodegenerative disease community. His work bridges clinical neurology with advanced neuroimaging and molecular research, establishing him as a key figure in contemporary neurodegeneration research.
Function/Biology
In his clinical and research roles, Rowe specializes in the diagnosis and investigation of complex neurodegenerative conditions that present with overlapping motor and cognitive symptoms. His expertise encompasses the full spectrum of frontotemporal lobar degeneration (FTLD) disorders, including behavioral variant frontotemporal dementia (bvFTD), primary progressive aphasia (PPA), and disorders with prominent motor features such as progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). Rowe utilizes advanced neuroimaging techniques, including structural and functional magnetic resonance imaging (MRI), positron emission tomography (PET), and diffusion tensor imaging (DTI), to characterize the pathological changes occurring in these conditions.
Role in Neurodegeneration
Rowe's contributions to neurodegeneration research have fundamentally advanced understanding of how genetic mutations produce phenotypic diversity in FTLD. His work has been instrumental in clarifying the clinicopathological heterogeneity seen in frontotemporal dementia, helping establish neuroimaging biomarkers that can distinguish between different pathological substrates underlying clinically similar presentations. Through systematic investigation of patient cohorts carrying mutations in genes such as GRN (progranulin), MAPT (microtubule-associated protein tau), and C9ORF72 (chromosome 9 open reading frame 72), Rowe has helped delineate how distinct molecular pathologies produce characteristic patterns of neurodegeneration visible on imaging studies.
Molecular Mechanisms
Rowe's research has illuminated the molecular mechanisms linking genetic mutations to neuronal loss patterns. In GRN-related FTD, his work has characterized how haploinsufficiency of progranulin affects lysosomal function and neuroinflammation, contributing to selective vulnerability of anterior temporal and orbitofrontal regions. In C9ORF72-associated disease, his investigations have explored how aberrant RNA foci and dipeptide repeat proteins trigger neurodegeneration, often with preferential involvement of motor cortex, brainstem, and spinal cord. His studies of tau pathology in MAPT mutations have demonstrated how different mutations produce distinct spatiotemporal patterns of tau accumulation, correlating with specific clinical phenotypes including corticobasal syndrome or progressive supranuclear palsy presentations.
Clinical/Research Significance
Rowe's research has immediate clinical relevance for patient care and therapeutic development. By establishing quantitative neuroimaging signatures associated with specific genetic mutations, his work enables earlier diagnosis in symptomatic and presymptomatic mutation carriers. This capability is crucial for clinical trial recruitment, as biomarker-defined cohorts with predicted disease progression trajectories facilitate identification of treatment effects. His longitudinal imaging studies have provided natural history data essential for understanding disease progression rates and mechanisms, informing the design of disease-modifying therapeutic trials. Additionally, Rowe's work has contributed to international standardization of imaging protocols for FTLD research, enhancing comparability across studies and facilitating multi-center investigations.
Related Entities
Rowe's research intersects with multiple fields and collaborations within neurodegenerative disease research. His work relates closely to studies of protein misfolding mechanisms, particularly regarding tau and TDP-43 pathology. Collaboration with molecular neuroscientists has elucidated links between genetic mutations and downstream pathological cascades. His clinical work interfaces with genetic counseling services and presymptomatic screening programs for familial FTD. Additionally, his research contributes to broader understanding of neuroinflammation, mitochondrial dysfunction, and proteostatic failure common across multiple neurodegenerative diseases.